- Cannabix Technologies (CSE:BLO) reports that its technology has been used to quantify delta-9 THC levels from smoking and edibles in people
- Delta-9 THC is the component in cannabis that causes impairment and the company’s Mass Spectrometer Breath Sampler (MSBS) technology along with the Breath Collection Unit (BCU) represents a means to test for recent use of marijuana
- This emerging capability represents a significant milestone for the company and a major leap forward in the arena of drug testing
- Cannabix Technologies last traded at $0.29 per share
Cannabix Technologies (CSE:BLO) reports that its breathalyzer technology has been used to quantify delta-9 THC levels from smoking and edibles in people.
Delta-9 THC is the component in cannabis that causes impairment and the company’s Mass Spectrometer Breath Sampler (MSBS) technology along with the Breath Collection Unit (BCU) represents a means to test for recent use of marijuana.
This emerging capability represents a significant milestone for the company and a major leap forward in the arena of drug testing. Virtually all levels of law enforcement, government, and industry have an interest in quantifying THC levels in breath in an efficient and reliable manner that will enable the ability to correlate breath concentrations with established blood levels.
In recent months, the company has developed the capability to quantify delta-9 THC in breath samples using its proprietary technology. The company’s team of scientists have quantified delta-9 THC in human breath samples using proprietary hardware and methods.
The team is using deuterated delta-9 THC (THC-D3) as an internal standard to generate a calibration curve for THC quantification in breath samples (ng/cartridge). Currently, a limit of detection and limit of quantification have been achieved with human subjects in the low picogram range. This allows detection of THC from smoking and edibles up to four hours after consumption.
The company added that the quantification of delta-9 THC in breath presents an opportunity to help establish a legal limit for THC in breath, a limit that has not yet been achieved.
In August 2023, the U.S. Department of Health and Human Services has recommended to the Drug Enforcement Administration that marijuana be reclassified as a lower-risk, Schedule III controlled substance, from its current Schedule I status.
If the reclassification is accepted, it can be reasonably expected that even more cannabis-based pharmaceutical and recreational products will be available to the public, further increasing the need for THC testing technology for public safety purposes.
Cannabix Technologies develops marijuana and alcohol breathalyzer technologies for law enforcement, workplaces, and laboratories.
Cannabix Technologies Inc. last traded at $0.29 per share.
Join the discussion: Find out what everybody’s saying about this stock on the INSERT Cannabix Technologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
